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ORIGINAL ARTICLE
Effects and safety of delayed versus early umbilical cord clamping in
newborns of HIV-infected mothers
L. Pogliania, P. Erbaa, P. Nanninia, V. Giacometa and G. V. Zuccottia,b
aDepartment of Pediatrics, ASST-FBF-Sacco, Sacco Hospital, University of Milan, Milan, Italy; bDepartment of Pediatrics,
ASST-FBF-Sacco, Buzzi Children’s Hospital, University of Milan, Milan, Italy
ABSTRACT
Objective: To investigate the effect of a 2 minutes-delayed cord clamp (DCC) versus early cord
clamp (ECC) on neonate haemoglobin concentration 24 hours and 1 month after birth, and
assess the safety of DCC concerning the risk of HIV infection.
Design: Sixty-four mother-infant peers were enrolled. All mothers were on stable ARV therapy.
Viral load, CD4þ count and blood haemoglobin (Hb) concentrations 24 hours before delivery
were collected from all mothers and their infants.
Methods: All patients were enrolled at the Department of Paediatrics, AO FBF Sacco Hospital in
Milan, and were followed until 18 months after birth. Women with haematological diseases and
obstetrical complications were excluded. All of 64 mother and infants couples (32 ECC group
and 32 DCC group) completed the study. ECC and DCC are defined as application of umbilical
clamp within 30 seconds and 120 seconds after birth, respectively.
Results: Mean birth weight was significantly higher in the DCC compared with ECC group. Mean
Hb levels at birth were significantly higher in DCC than in ECC group (p¼ .05): this difference
persisted at 1 month of life. All newborns showed negative viral load.
Conclusions: DCC 2 minutes after birth is proven to be a safe procedure, particularly beneficial in
newborns from HIV mothers. The risk of anemia is significantly decreased at 24 hours after birth
and persists at age of 1 month without any increased risk of neonatal jaundice or polycitemia.
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Introduction
Perinatal transmission of HIV-infection from HIV-
infected mothers to newborns can be prevented by
antiretroviral (ARV) therapy during pregnancy, intrapar-
tum and postnatal prophylaxis [1]. The use of Highly
Active Antiretroviral Therapy (HAART) in pregnancy
has decreased the prevalence of HIV vertical transmis-
sion to less than 1% in developed countries, although
relevant side effects [2]. One of the antiretroviral
drugs, 30-azido-30-thymidine, AZT (zidovudine), is com-
monly used as a component of treatment for pregnant
HIV-infected mothers and also as postnatal prophylaxis
in newborns. Common adverse effects are dose- and
time-dependent anaemia (34% of treated patients),
often accompanied by macrocytosis, while bone mar-
row failure is observed more rarely [3,4].
Infants born to anaemic mothers during pregnancy
are twice more likely to be anaemic (8.6 versus 3.8%)
at birth than ones born to nonanaemic mothers [5,6].
Delayed cord clamping (DCC) is one of the action
used for preventing postpartum haemorrhage of
mothers, increasing haemoglobin levels and body iron
stores in infant and reducing blood transfusion in pre-
term [7]. Currently, the World Health Organization
(WHO) and the European Resuscitation Council, recom-
mend DCC to improve maternal and infant health and
nutritional outcomes [8–11].
Prenatal iron deficiency affects the normal develop-
ment of brain structures, neurotransmitter systems and
myelination [12]; therefore, anaemia and iron defi-
ciency are largely demonstrated to be associated with
impaired psychomotor development, impaired per-
formance in language tests, and in motor and coordin-
ation skills [13–15]. DCC performed in the first minutes
after birth, allows newborn, either to anaemic and
nonanaemic mothers, to receive a substantial blood
transfusion from placenta and increase blood volume
of an average 32%, leading to obtain higher birth-
weight and haemoglobin concentration [8]. Few
adverse effects such as hyperbilirubinemia, polycythae-
mia and respiratory symptoms have been reported
[16,17]. However, a recent Cochrane review, based on
term infants, reports no significant differences
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regarding neonatal morbidities (low Apgar score,
admission to the neonatal intensive care unit, jaundice,
polycythaemia) between the use of early cord clamp-
ing (ECC) and DCC [18].
The aims of our study were primarily to investigate
the effect of a 2minutes-DCC versus ECC on neonate
haemoglobin status 24 hours and 1 month after birth,
secondarily to assess the safety of DCC concerning the
risk of HIV infection by vertical transmission.
Materials and methods
The study was conducted between January 2012 and
March 2016 in the Paediatric Department of Luigi
Sacco Hospital, University of Milan, one of the referral
centres for infectious diseases in Italy. Informed con-
sent was collected from all participants, as appropriate.
The study has been conducted according to the princi-
ples expressed in the Declaration of Helsinki. HIV-
infected pregnant women were considered eligible for
the enrolment if on stable ARV therapy, without evi-
dence of any medical or obstetrical complications. The
following data were collected from mothers: age, eth-
nicity, antiretroviral therapy, viral load, CD4þ count
and blood haemoglobin (Hb) concentration 24 hours
before delivery. Women with haematological diseases
were excluded from this study. Mothers’ anaemia was
defined by haemoglobin concentration below 11 g/dL,
according WHO definition [19]. The following data
were collected from infants: gestational age, type of
delivery, anthropometric parameters (weight, length,
head circumference), Apgar score, Hb concentrations
24 hours and 1 month after birth, HIV-RNA and CD4þ
count. Anaemia in newborns was defined as a Hb con-
centration below 13.5 g/dL [20].
Mothers and infants were divided in two groups:
who received ECC (group 1) and DCC (group 2). ECC
was defined as application of a clamp to the umbilical
cord within 30 seconds after birth and it was the
standard method in our hospital in the period
between January 2012 and January 2014. Delayed
cord clamping was defined as application of a clamp
to the umbilical cord 120 seconds after birth, using a
chronometer, and it was performed in our hospital,
between February 2014 and March 2016: the neonate
was placed between supine mother’s thighs and the
cord was clamped while placenta remaining in utero.
The umbilical cord was cut in the operating room by
the obstetrician after counting the time by a midwife.
A total of 32 newborns who received ECC (group 1)
and 32 newborns who received DCC (group 2) were
evaluated during the study period. All infants were
born by caesarian section.
Newborns’ physical examination was assessed within
1 hour after delivery and again 24, 48, 72 hours later by
paediatric staff. The evaluation included neurological
and dermatological assessment (in particular the pres-
ence of jaundice), gastrointestinal and respiratory func-
tions. All neonates, regardless the timing of umbilical
cord clamping, were managed equally including labora-
tory testing, nutritional management with formula and
antiretroviral prophylaxis, which was performed with
zidovudine 2mg/kg/dose QID for 4–6 weeks, started
6 hours after birth [21]. Serum bilirubin assessments
were performed 72 hours after birth, or before if
required and evaluated according to Bhutani
Nomogram [22]. Symptomatic polycythaemia was
defined as haematocrit over 65% with evidence of new-
born distress as assessed by the paediatric staff [23,24].
HIV-vertically transmission was excluded at birth,
and at 1, 3, 6 and 12 months of age by HIV-DNA (RT-
PCR) or HIV-RNA (RT PCR) assessment, depending on
maternal ethnicity. HIV-Ab (Elisa/EIA) was performed at
18 months of age for definitive exclusion of HIV trans-
mission. Blood samples were collected for Hb level
24 hours and 1 month after birth.
Data analysis was performed with STATAVR 14.
Baseline characteristics and measurements were com-
pared across groups with chi-square statistic for cat-
egorical variables and Student’s t-test for continuous
Table 1. Mothers’ and newborns’ characteristics.
ECC (<30 sec) Group 1 DCC (120 sec) Group 2
Mothers’ Characteristics
Age yrs mean (range) 33.9 (21.6–43) 34.7 (23.8–44.1)
Ethnia (Caucasian/Other) 21/11 16/16
Antiretroviral Therapy (PI based regimen) 28/32 25/32
HIV-RNA <37 cp/mL 30/32 29/32
Hb g/dL mean (range) 10.9 (7.3–13.4) 11.0 (7.4–13.3)
Newborns’ Characteristics
Gestational Age wks mean (range) 38 (33þ4 40þ4) 38þ2 (37–39þ5)
Weight g mean (range) 2880 (1360–3485) 3159 (2695–3910)
Male/Female 19/13 17/15
Apgar <7/10 4/32 0/32
24 h Hb g/dL mean value (range) 15.1 (12.6–21.2) 17.4 (13.1–20.9)
Phototherapy 0/32 0/32
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variables. Group means were compared by using the t
student significant difference test. All results were
based on two-tailed tests and a p value of .05 was
used as the criterion for significance.
Results
Sixty-four mother–infant peers participated at the
study, recruited for 4 years from January 2012 to
November 2015. Regarding maternal characteristics and
neonatal baseline data, there were no significant differ-
ences between the DCC and ECC groups (Table 1).
Maternal haemoglobin values 24 hours before deli-
very were not significantly different between ECC and
DCC group. No significant differences were found in
Apgar score between the two groups, no infant required
neonatal intensive care, nor phototherapy for jaundice.
Mean birth weight was significantly higher in the
DCC compared with ECC group (þ 282 g). Hb values
were obtained at 24 hours of life: 9 infants resulted to
be anaemic, respectively 3% in DCC and 25% in ECC
group. Only anaemic infants were treated with bisgly-
cine chelated iron supplementation (TecnoferVR , Lab.
Baldacci Spa) at the dose of 0.75mg/kg/day up to a
maximum of 7.5mg/day.
Mean Hb levels were significantly higher in DCC
(17.36 g/dL, range 13.1–21.1 g/dL) than in ECC (15.1 g/
dL, range 10.9–21.2 g/dL) group (p¼ .05). The difference
in Hb concentration persisted at 1 month of life, despite
iron supplementation in anaemic newborns tested at
24 hours from birth: in the DCC group the mean haemo-
globin level was 10.9 g/dL while in ECC was 9.7 g/dL
(p< .05). No more difference in Hb concentration was
detected after 12 months. All newborns showed HIV-
PCR negative at birth, at 1, 6, 12 and 18 months of life.
Discussion
Perinatal antiretroviral therapy has dramatically
reduced the risk of HIV vertically transmission.
Evaluation of infant toxicity from exposure to maternal
HAART in pregnancy regards principally haematologic
toxicity. Several antiretroviral drugs, especially zidovu-
dine and others nucleoside reverse transcriptase inhib-
itors (NRTIs), are known to cause anaemia both in
adults and in children. Currently, WHO recommends
DCC in HIV positive pregnant women: it is a quick and
inexpensive method of enhancing haematologic status,
preventing neonatal anaemia by enriching iron stores
and ferritin levels and improving neurodevelopmental
outcome. Moreover, a longer duration of placental
transfusion allows an increase supply of valuable stem
and progenitor cells, allows a better a fetal-to-neonatal
transition and a greater red cell mass for oxygenation
and iron content essential for the maturation of the
preoligodendrocytes and myelin production [18,25,26].
DCC may be one of the procedures that offer
infants many advantages both in the short and long-
term. Several studies support the benefits of DCC and
demonstrate the absence of association with increased
risk of hyperbilirubinemia or symptomatic polycythae-
mia. Consistently with literature data, mean birth-
weight in DCC group is significantly higher than ECC
group [27,28].
DCC 2minutes after birth is particularly beneficial in
newborns from HIV mothers due to high prevalence of
anaemia in this population. Compared with ECC, the
risk of anaemia is significantly decreased at 24 hours
after birth and persists at age of 1 month. We didn’t
found any increased risk of neonatal jaundice or poly-
cythaemia associated to DCC. WHO guidelines suggest
DCC in HIV women to improve maternal and infant
health and nutrition outcomes because benefits out-
weigh “the theoretical, and unproven, harm” of virus
transmission. In our knowledge, till now no data are
available regarding the correlation between DCC and
vertically HIV-infection [9].
This study has several limitations: first of all, the lim-
ited number of patients, secondly the biased evalu-
ation of anaemia at 1 month after birth, affected by
iron supplementation and the limited follow up time
after birth. Nevertheless, the difference in Hb concen-
tration persisted at 1 month of life. A future aim of
this study will be the evaluation of neurocognitive and
linguistic performance in newborns from DCC group
versus ECC.
Conclusions
Despite the advances in the past decades in caring
HIV-infected mothers, DCC remains a common proce-
dure both in high and low-income countries and our
results confirm the efficacy of DCC in term of
increased haemoglobin level in newborns and the
safety of this procedure regarding the vertical trans-
mission of HIV virus.
Given its cost-effectiveness and simplicity, the DCC
practice in HIV population could be crucial in improv-
ing child health especially in developed countries,
where maternal high viral load, or a not completely-
negative viral load at the moment of delivery are still
common.
Disclosure statement
No potential conflict of interest was reported by the authors.
THE JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE 3
References
[1] Centers for Disease Control and Prevention (CDC).
Zidovudine for the prevention of HIV transmission
from mother to infant. MMWR Morb Mortal Wkly Rep.
1994;43(16):285–287.
[2] Thorne C, Newell ML. Mother-to-child transmission of
HIV infection and its prevention. Curr HIV Res.
2003;1(4):447–462.
[3] Snowdin JW, Hsiung CH, Kesterson DG, et al. Effects
of zidovudine treatment on heart mRNA expression
and mitochondrial DNA copy number associated with
alterations in deoxynucleoside triphosphate compos-
ition in a neonatal rat model. Antimicrob Agents
Chemother. 2015;59(10):6328–6336.
[4] Gill PS, Rarick M, Brynes RK, et al. Azidothymidine
associated with bone marrow failure in the acquired
immunodeficiency syndrome (AIDS). Ann Intern Med.
1987;107(4):502–505.
[5] Gedefaw L, Yemane T, Sahlemariam Z, et al. Anemia
and risk factors in HAART naïve and HAART experi-
enced HIV positive persons in South West Ethiopia: a
comparative study. PLoS One. 2013;8(8):e72202.
[6] Nandlal V, Moodley D, Grobler A, et al. Anaemia in
pregnancy is associated with advanced HIV disease.
PLoS One. 2014;9(9):e106103.
[7] Van Rheenen PF, Brabin BJ. A practical approach to
timing cord clamping in resource poor settings. BMJ.
2006;333(7575):954–958.
[8] Yao AC, Moinian M, Lind J. Distribution of blood
between infant and placenta after birth. Lancet.
1969;2(7626):871–873.
[9] World Health Organization. WHO handbook for guide-
line development. 2012. [cited 2014 Jun 19]. Available
from: http://apps.who.int/iris/bitstream/10665/75146/
1/9789241548441
[10] Wyllie J, Perlman JM, Kattwinkel J, et al. Part 7:
Neonatal resuscitation: 2015 International Consensus
on Cardiopulmonary resuscitation and Emergency car-
diovascular care science with treatment recommenda-
tions. Resuscitation. 2015;95:e169–e201.
[11] Wyckoff MH, Aziz K, Escobedo MB, et al. Part 13:
Neonatal resuscitation: 2015 American Heart
Association guidelines update for cardiopulmonary
resuscitation and emergency cardiovascular care.
Circulation. 2015;132(18Suppl2):S543–S560.
[12] Alwan NA, Hamamy H. Maternal iron status in preg-
nancy and long-term health outcomes in the off-
spring. J Pediatr Genet. 2015;4(2):111–123.
[13] Lozoff B, Jimenez E, Hagen J, et al. Poorer behavioral
and developmental outcome more than 10 years after
treatment for iron deficiency in infancy. Pediatrics.
2000;105(4):E51.
[14] Andersson O, Lindquist B, Lindgren M, et al. Effect of
delayed cord clamping on neurodevelopment at 4
years of age: a randomized clinical trial. JAMA Pediatr.
2015;169(7):631–638.
[15] Zonnenberg IA, Vermeulen RJ, Rohaan MW, et al.
Severe neonatal anaemia, MRI findings and neurode-
velopmental outcome. Neonatology. 2016;
109(4):282–288.
[16] McDonald SJ, Middleton P, Dowswell T, et al. Effect of
timing of umbilical cord clamping of term infants on
maternal and neonatal outcomes. Cochrane Database
Syst Rev. 2013;7:CD004074.
[17] Mercer JS, Erickson-Owens DA, Vohr BR, et al. Effects
of placental transfusion on neonatal and 18 month
outcomes in preterm infants: a randomized controlled
trial. J Pediatr. 2016;168:50–5.
[18] McLean E, Cogswell M, Egli I, et al. Worldwide preva-
lence of anaemia 1993–2005: WHO global database on
anaemia. Geneva: World Health Organization; 2008.
[19] Wang M. Iron deficiency and other types of anemia in
infants and children. Am Fam Phys. 2016;93(4):
270–278.
[20] Sperling RS, Shapiro DE, McSherry GD, et al. Safety of
the maternal-infant zidovudine regimen utilized in the
Pediatric AIDS Clinical Trial Group 076 Study. AIDS.
1998;12(14):1805–1813.
[21] AAP. Management of hyperbilirubinemia in the new-
born infant 35 or more weeks of gestation. Pediatrics.
2004;114(1):297–316.
[22] Sarkar S, Rosenkrantz TS. Neonatal polycythemia and
hyperviscosity. Semin Fetal Neonat Med. 2008;13(4):
248–255.
[23] Mimouni FB, Merlob P, Dollberg S, et al. Neonatal
polycythaemia: critical review and a consensus state-
ment of the Israeli Neonatology Association. Acta
Paediatr. 2011;100(10):1290–1296.
[24] Connor JR, Menzies SL. Relationship of iron to oligo-
dendrocytes and myelination. Glia. 1996;17(2):83–93.
[25] Gonzales-Portillo GS, Reyes S, Aguirre D, et al. Stem
cell therapy for neonatal hypoxic-ischemic encephal-
opathy. Front Neurol. 2014;5:147.
[26] Mercer JS, Erickson-Owens DA, Collins J, et al. Effects
of delayed cord clamping on residual placental blood
volume, hemoglobin and bilirubin levels in term
infants: a randomized controlled trial. J Perinatol.
2017;37(3):260–264.
[27] Garabedian C, Rakza T, Drumez E, et al. Benefits of
delayed cord clamping in red blood cell alloimmuni-
zation. Pediatrics. 2016;137(3):e20153236.
[28] Orlandini C, Torricelli M, Spirito N, et al. Maternal
anemia effects during pregnancy on male and female
fetuses: are there any differences? J Matern Fetal
Neonatal Med. 2017;30(14):1704–1708.
4 L. POGLIANI ET AL.
